Skip to main content

Department of Transfusion Medicine

Symposium Description

Forty-First Annual Symposium: September 22, 2022

Description: This program is designed to provide attendees with practical information about recent developments, current practices, controversies and laboratory management issues relative to transfusion medicine.

Who Should Attend: This program will be of interest to all healthcare providers who participate in the collection, production, transfusion and monitoring of blood products.

Learning Objectives
Upon the completion of this activity, participants should be able to:

  • Describe how CAR T-cell therapies are developed and administered.
  • Summarize clinical results with CAR T-cell therapies for lymphoma.
  • Interpret clinical results with CAR T-cell therapies for multiple myeloma.
  • Describe the phenomena of red cell alloimmunization and evanescence.
  • List the consequence of alloimmunization.
  • Detail attempts to exchange alloantibody history past and present.
  • Discuss the question: Does xenotransplantation provide a definite option to overcome organ shortage?
  • Discuss tests performed during COVID pandemic and collection of Convalescent COVID Plasma. 
    Describe two effective strategies to increase the recruitment of Black blood donors.
  • Discuss how mistrust in the medical community can affect blood donation by Black donors.
  • List new post-pandemic challenges for blood collectors in procuring donors and the risk to the resiliency and stability of the blood supply
  • Define acute vs chronic blood shortages.  List some of the causes and solutions of blood shortages.
    Discuss a model for tracking transfusions.
  • List four adverse reactions which have been associated with the administration of Rho(D) Immune Globulin (RhIg).
  • Review the strategies used for mobilizing hematopoietic stem cells in patients with sickle cell disease for efficient autologous stem cell apheresis collection.
  • Review the differences between classical myasthenia gravis and immune-related myasthenia gravis and use of plasma exchange for this rare but serious complication of immune checkpoint inhibitors (ICI) therapy.

Level of Instruction
Intermediate to Advanced

This program has a pending application of for continuing education credits.

NOTE: PDF documents require the free Adobe Reader.

This page last updated on 08/04/2022

You are now leaving the NIH Clinical Center website.

This external link is provided for your convenience to offer additional information. The NIH Clinical Center is not responsible for the availability, content or accuracy of this external site.

The NIH Clinical Center does not endorse, authorize or guarantee the sponsors, information, products or services described or offered at this external site. You will be subject to the destination site’s privacy policy if you follow this link.

More information about the NIH Clinical Center Privacy and Disclaimer policy is available at